CD70 and cancer: We hypothesized that the anti-CD70 VHH recognizes a distinct epitope on the CD70 antigen that is different from the one recognized by the mouse anti-human CD70 antibody, which represents a potential advantage for detection of this target in cancer patients treated with CD70-targeting therapies.